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ABSTRACT  
The world is running out of antibiotics. Between 1940 and 1962, more than 20 new classes of antibiotics were marketed. Since then, only two new 
classes of antibiotics were marketed. Now, not enough analogues are reaching the market to stem the tide of antibiotic resistance, particularly 
among gram-negative bacteria which indicates the need of novel antibiotics for their effective action. This review describes those antibiotics in late-
stage clinical development. Most of them belong to existing antibiotic classes and a few with a narrow spectrum of activity are novel compounds 
directed against novel targets. The reasons for some of the past failures to find new molecules and a path forward to help attract investments to 
fund the discovery of new antibiotics are described. 
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The antibiotics are the cornerstones of recent medicine after the 
entry of penicillin, which came into widespread use in the beginning 
of the 1940s. [1] By 1950s, multiple numbers of newer classes of 
antibiotics came into the scene, over the next twenty years. [2] 
Nowadays it is difficult to treat and do certain medical procedures 
which are extensively used, like chemotherapy, organ transplants, 
joint operations or the provision of care for premature babies 
without the antibiotics [1]. Moreover, they can control both 
morbidity and mortality rate in humans and animals. [3] To brief 
outing, they have become the lifesaving treatment for all types of 
infections in humans as well as animals. The timeline of new class 
antibiotics has been given in table 1. 
 
Table 1: Time line of antibiotics 






























Now, however, two developments are resulting in more and more 
difficult to treat the bacterial infections with the antibiotics 
successfully, including the increasing number of antibiotic-resistant 
pathogens and the second one is that the number of new antibiotics 
developed since the 1970s has decreased [4]. It was estimated that 
infections that can be treated completely are also becoming more 
complicated to treat, increasing costs of healthcare facilities, and 
patient mortality is increasing with costs to the society. The 
antibiotic effectiveness has to decrease now and many of the 
microorganisms are resistant to multiple antibiotics [5]. The issue of 
antibiotic resistance, though not new, has amplified in the previous 
10 to 15 y and creates a serious threat to the treatment of infections. 
Certain new investigational studies were reported that, among all 
the multidrug-resistant pathogens like S. aureus and P. aeruginosa, 
Acinetobacter species are the major infective organism which can 
cause even life-threatening resistant infections. The improper intake 
of antibiotic dosage or lack of sensitive antibiotic agents to fight 
against these types of organisms may be the reason for the 
occurrence of such infections [6]. 
Despite this increase in the multidrug-resistant pathogens, the 
development of antibacterial agents is declining, [7] that is, there are 
not enough antibiotics for treating such infections [4]. This antibiotic 
deficit will become more and more problematic in the years to come. 
As per World Health Organization (WHO), the antibiotic resistance is 
one among the serious hazard to human health and the 
consequences of antibiotic-resistant bacterial infections are greater 
than ever [4]. So, new antibiotics are critically needed to alleviate 
the problems associated with this antibiotic resistance [8, 9]. The 
Infectious Diseases Society of America (IDSA, 2010) estimated that 
at least another 10 antibiotics, which are active against these 
superbugs, are required to enter the market within ensuing ten 
years [10]. It ought to be noted that antibiotics, which were already 
in market use are complex natural products with multiple binding 
sites on the target, making it less likely for resistance selection. 
Moreover, the prevalence of treatment difficulty for both resistant 
and multi-resistant nosocomial organisms are greatly rising, both for 
Gram-negative and Gram-positive bacteria among this; gram-
negative organisms are producing a greater threat [11]. 
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Thus, the demand for new antibiotics is critical for some gram-
negative microbes as compared to gram-positive microbes since the 
new molecules or compounds will produce action in new pathways 
to eradicate such microbes [12]. Generally, small proteins are the 
greatest source of new antibiotics called antimicrobial peptides 
(AMPs) and many of these AMPs are derived from natural molecules 
[13]. The current study reviews all the current articles on clinically 
developing antibiotics and describes their needs and scope in the 
market. 
Search criteria  
Articles related to new antibiotics and their developments were 
reviewed for the study, most of them were from Pubmed databases. 
Articles between the years of 2000 and 2017 were selected for 
reviewing and the points were extracted. Primary resources were 
given the first preference for reviewing.  
Approval and development of antibiotics from the ‘Golden Era’ 
The response to the entry of any new antibiotic has lead to the 
development of resistant bacterial variants so, new antibiotic 
compounds should be needed constantly to alleviate the associated 
problems. During the "golden era" of antibiotic evolution, that is, in the 
years of 1940s to 1970s, new antibiotics with new actions were 
incessantly developed, which made it possible to manage the threat of 
gradually rising resistant strains. [8] The European Medicines Agency 
(EMA) and the American Food and Drug Administration (FDA) were the 
two agencies responsible for making the approval decisions for new 
antibiotics. The new antibiotics, which are approved in the year of 2000 
and 2011, are listed below (table 2). 
  
Table 2: Status of antibiotics approved by the FDA and the EMA between 2000 and 2011 
Substance Class Rejected by FDA Approved by FDA Approved by EMA 
Linezolid Oxazolidinones  2000  
Ertapenem Carbapenems  2001 2002 
Cefditoren Cephalosporines  2001  
Gemifloxacin Fluoroquinolones  2003  
Daptomycin Lipopeptides  2003 2006 
Telithromycin Macrolides  2004  
Tigecycline Glycylcyclines  2005 2006 
Faropenem Penems 2006   
Retapamulin Pleuromutilins  2007 2008 
Dalbavancin Glycopeptides 2007   
Doripenem Carbapenems  2007  2008 
Oritavancin Glycopeptides 2008   
Cethromycin Macrolides 2009   
Cethromycin Macrolides 2009   
Iclaprim Trimethoprims 2009   
Besifloxacin Fluoroquinolones  2009  
Telavancin Glycopeptides  2009 2011 
Ceftobiprole Cephalosporines 2009   
Fidaxomicin Lipiarmycins  2011 2011 
Colistimethate sodium Colistin   2012 
Ceftaroline Cephalosporines  2010 2012 
 
However, the world’s capacity for antibiotic discovery is already 
reducing the rate of emergence of bacterial resistance, and which 
indicates the necessity of another new class of antibiotics to be 
introduced in the market (Figure1). Fig. 1 showed a line drawing of 
total number of newer classes of antibiotics that entered to the 
market in the years of 1940s and 1960s, the two new classes since 
2000, and further 20-40 new classes were required to support 
medicine in the future years from now [6]. 
 
 
Fig. 1: Number of antibiotics in the market and the predictions of new antibiotics needed for the future 
 
Novel antibiotics in recent years  
The majority of new antibiotic substances is in the early phase of 
development is, phase 1 clinical trials [4]. The clinical trials for new 
antibiotics are believed to be cover disease indications even if it is 
the infection caused by more than one bacterial species [14]. The 
research updates showed that only two new classes of antibiotics 
were marketed in last 10 y and it may be due to the lack of 
development and almost all the pharmaceutical companies were 
concentrating only on analogue development which may be due to 
the high toxicity risks associated with the new classes [15]. At 
present, the environment has changed a little positively, and those 
who observing preclinical and clinical development strategies and 
activities have a reason to be more optimistic [11].  
Several compounds have been developed in various antibiotic 
classes which are against resistant organisms in the whole spectrum 
of multidrug-resistant (MDR) bacteria (fig. 2) [11]. 
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Fig. 2: New antibiotic compounds acting against resistant organisms 
 
Source Reference: https:/www.google.co.in.novelantibiotics 
diagram [16] 
Since most of the infections can be cured without antibiotic therapy, 
thus, new antibiotic approval is generally limited to complicated or 
more serious infections. The Infectious Diseases Society of America 
(IDSA) emphasizes that selecting the optimal drug regimen; dose, 
duration, and route of administration are a very important part in 
the stewardship practice. Furthermore, stewardship seeks to 
diminish the toxicity and other adverse events and also to lessen the 
costs of healthcare infections [16]. 
It is not easy to estimate the numbers of drugs in preclinical 
development, as most of them are not published or marketed [17]. 
Still, there are no antibiotics against the major gram-negative 
microorganisms such as K. pneumoniae, P. aeruginosa and A. baumanii 
in Phase II b and III and also the number of compounds (analogs of 
existing markets antibiotics) against these pathogenic organisms in 
earlier stages of development are also lessened. Since there are no 
new classes of antibiotics in the final phases of drug development, the 
new class antibiotics will not be introduced in the market in the short 
term [10, 18]. In the longer term, during the next 20 y, the probability 
of inventing twenty new antibiotic classes like many broad-spectrum 
antibiotics, as similar in 1940-1960s, looks to be remote, especially for 
multi-drug-resistant gram-negative microorganisms. 
Novel compounds against microorganisms which are under 
clinical development 
• Compounds against Gram-positive bacteria 
Novel long-acting lipoglycopeptides-oritavancin and dalbavancin 
Acute bacterial skin and skin structure infections (ABSSIs) are 
considered as the major bacterial infection and the frequent 
indications for antibacterial therapy, which are usually induced by 
Gram-positive bacteria like MRSA (Methicillin-resistant Staphylococcus 
aureus). With the introduction of the newer lipoglycopeptides with an 
extended elimination half-life, ABSSSI therapy may become more 
convenient. Oritavancin acts by inhibiting transglycosylation (like 
vancomycin), transpeptidation (like beta-lactams), and disruption of 
cell membrane integrity (like telavancin) [19] and results in quick 
bactericidal activity. It has a long elimination half-life of>300 h [20] 
and showed a strong bactericidal activity in a dose of 1200 mg in the in 
vitro PK/PD model [21]. 
Dalbavancin is another semisynthetic lipoglycopeptide which has 
been estimated for skin and soft tissue/skin structure infections, 
[22, 23] and also for catheter-associated bloodstream infections. Its 
half-life is about two weeks [24] also allowed for prolonged dosing 
intervals. Dalbavancin had a favorable safety profile with fewer 
adverse effects. It is estimated that the usage of dalbavancin was 
joined up with a significantly lower mortality (0.2 vs. 1.1 %). Finally, 
this has proceeded to the FDA approval of dalbavancin for ABSSSI 
caused by S. Aureus and S. pyogenes in May 2014. 
Drugs to destroy gram-negative bacteria and broad-spectrum 
antibiotics 
BAL30072 
BAL30072 is a monosulfactam antibiotic, have an action against 
carbapenem-resistant Enterobacteriaceae and non-ferments [25]. It 
is chemically related to aztreonam and coming under the class of 
beta-lactam antibiotic and inhibiting the cell wall synthesis of 
bacteria. Certain in vitro studies has shown that the combination of 
BAL30072 with BAL29880 or clavulanate can result in susceptibility 
rates of more than 90%. A study conducted in Thailand, with its 
laboratory strains (1026b, 1710b) and several strains which are 
isolated, it was observed that more than 93% of the isolates were 
susceptible to BAL30072 with minimal inhibitory concentrations 
(MICs) between 0.004-0.016 μg/ml [26]. BAL30072 showed high 
activity through a MIC 90 of 0.016 μg/ml as compared to 
ceftazidime, meropenem, and imipenem.  
Ceftolozane 
Ceftolozane with tazobactam is presently undergoing certain 
investigational studies for testing its action in complicated urinary 
tract infections (cUTIs), complicated intra-abdominal infections 
(cIAIs) and ventilator-associated pneumonia (VAP). It is a new 
cephalosporin which is structurally similar to ceftazidime, which 
active against Pseudomonas and also against bacteria-producing 
beta-lactamases such as TEM-1. [11] Ceftolozanealone cannot 
destoy or kill the bacteria-producing ESBL and carbapenemases. 
However, along with tazobactam, it can destroy most of the 
bacteria-producing ESBL and some anaerobes. The FDA approved 
ceftolozane/ tazobactam to treat adultscIAI and cUTI in December 
2014 [27]. 
Delafloxacin (fluoroquinolone) 
Delafloxacin is a fluoroquinolone and its efficacy is undergoing 
through various investigational studies. As compared with others, it 
has a substituent on the seventh position of the quinoline ring 
system which is not protonatable and causes a pKa shift. Generally 
fluoroquinolones are zwitterionic except delafloxacin and as a result, 
they are neutrally charged only at a physiological pH. The neutral 
charge is essential for membrane penetration. Delafloxacin 
permeates the membranes at lower pH as seen in the inflamed tissue 
[28, 29]. Generally, the pH levels are mildly acidic (about 5.5-6) in 
the inflammatory tissue of soft tissue infections, abdominal 
infections, or urinary tract infections, under these conditions, e. g., 
90% of moxifloxacin is in a cationic state, so it cannot permeate the 
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bacterial membranes. In contrast, delafloxacin is neutral at this pH 
and thereby leads to high cellular uptake [28]. 
Novel beta-lactamase inhibitors 
The beta-lactamase inhibitors which are available for the clinical 
application includes sulbactam, clavulanate, tazobactam, etc. 
Recently, these beta-lactamases increases the resistance particularly 
to Gram-negative bacillieg. oxacillinasescephalosporinases and the 
metallo-beta-lactamases. Novel beta-lactamase inhibitors (e. g., 
diazabicyclooctane-related substances) are also able to inhibit these 
enzymes to a different extent. They, therefore, contribute 
substantially to meet the increasing need for new drugs against 
ESBL or Klebsiella pneumonia carbapenemases (KPCs)-producing 
bacilli [11]. 
Antibiotics currently under clinical development  
SinceMarch 2017, about 41 novel antibiotics have been found to be 
under clinical investigation in the U. S. market for the management 
of potential bacterial infections. The achievement rate for such 
clinical drug development is low; the various study data showed 
that, generally, only 1 in 5 infectious disease products are entering 
into phase 1 clinical trial (human testing) [30]. The present 
antibiotic pipeline, on the basis of currently available information, is 
given in table 3. It will be revised in a periodic manner. 
 
Table 3: List of compounds which are under clinical development 
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LCB01-037110 LegoChemBioscie
nces Inc. 
Oxazolidinone 50S subunit 
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No No Bacterial infections 
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ofbacterial 
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Pleuromutilin[16] 50S subunit 
ofbacterial 
ribosome 





prosthetic jointinfections [6] 
Omadacycline ParatekPharmace
uticalsInc. 
Tetracycline 30S subunit 
of bacterial 
ribosome 
Yes Possibly CAP, ABSSIs 
 
CONCLUSION  
There are many promising antibiotic compounds which are 
currently under clinical development which will be open up the 
possibilities for treating various life-threatening infections, but 
among them very few are reaching the stage of human testing. The 
resistance mechanisms are the main problem associated with the 
antibiotic therapy, but this will not stop with the entry of the new 
drugs into the market. Therefore, the race must continue, and drugs 
with new actions need to be investigated and tested for human use. 
The requirements should include that, the product is within the 
scope of combination regimes, should be made possible as this could 
help to delay the development of resistance. 
AUTHORS CONTRIBUTIONS 
All the author have contributed equally 
CONFLICT OF INTERESTS  
Declared none 
REFERENCES 
1. White AR. Effective antibacterials: at what cost? The economics 
of antibacterial resistance and its control. J Antimicrob 
Chemother 2011;66:1948-53. 
2. Infectious Diseases Society of America. Bad drugs, No Drugs. 
Alexandria, Virginia. Infectious Diseases Society of America; 2004. 
3. Sabiha I, Twinkle G, Aarti A, Nilanjan D. A comparative study of 
an antimicrobial profile having broad-spectrum bacteriocins 
against antibiotics. Asian J Pharm Clin Res 2017;10:44-7. 
4. Antibiotics research: problems and perspectives Statement. 
Academy of Sciences and Humanities in Hamburg German 
National Academy of Sciences Leopoldina; 2013. 
5. Hellen G, Molly MP, Suraj P, Sumanth G, Jordan L, Devra B, et al. 
State of the World’s Antibiotics: CDDEP; 2015. 
6. Sadiya Z, Syed B, Shym N, Tanveer A, Faaiza Q. Synergistic 
combinations of broad-spectrum antibiotics against 
acinetobacterspp. Int J Pharm Pharm Sci 2015;7:214-7. 
7. Conly JM, Johnston BL. Where are all the new antibiotics? The new 
antibiotic paradox. Can J Infect Dis Med Microbiol 2005;16:159-60. 
8. Dalhoff A. Resistance surveillance studies: a multifaceted problem-
the fluoroquinolone example. Infection 2012;40:239–62. 
9. Lübbert C, Becker RD, Rodloff AC, Laudi S, Busch T, Bartels 
M, et al. Colonization of liver transplant recipients with KPC-
producing Klebsiellapneumoniaeis associated with high 
infection rates and excess mortality: a case–control analysis. 
Infection 2014;42:309–16. 
10. Anthony RM, Gerry H, Yanmin H. Novel classes of antibiotics or 
more of the same? Br J Pharmacol 2011;163:184–94. 
11. Draenert R, Seybold U, Grutzner E, Bogner JR. Novel antibiotics: are 
we still in the pre–post‑antibiotic era? Infection 2015;43:145–51. 
12. Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. 
Science 2009;325:1089-93. 
13. Ivan DB, Xian Jin, Ricardo V, Daniel P, Sacha J, Bee Ha Gan, et al. 
Chemical space guided discovery of antimicrobial bridged 
bicyclic peptides against pseudomonas aeruginosa and its 
biofilms. Chem Sci 2016;7:1-812. 
14. Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon 
BP, et al. New antibiotic kills pathogens without detectable 
resistance. Nature 2015;517:455–9. 
15. Mima T, Brian HK, Drew AR, Malcolm GPP, Eric D, Herbert P, et 
al. In vitro activity of BAL30072 against Burkholderia 
pseudomallei. Int J Antimicrob Agents 2011;38:157–9. 
16. New antibiotics acting against resistant microorganisms. Available 
from: https:/www.google.co.in.novelantibioticsdiagram. [Last 
accessed on 09 Jul 2017] 
17. Infectious Diseases Society of America (IDSA), Promoting 
Antimicrobial Stewardship in Human Medicine. Available from: 
https://www.idsociety.org/Stewardship_Policy/. [Last 
accessed on 08 Jul 2017] 
18. Lambert PA. Bacterial resistance to antibiotics: modified target 
sites. Adv Drug Delivery Rev 2005;57:1471–85. 
19. Singh SB, Barrett JF. Empirical antibacterial drug discovery–
foundation in natural products. Biochem Pharmacol 2006; 
71:1006-15. 
20. Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism 
of action. Clin Infect Dis 2012;54:214–9. 
21. Rubino CM, Van Wart SA, Sujata MB, Paul GA, Jill SM, Alan F. 
Oritavancin population pharmacokinetics in healthy subjects and 
patients with complicated skin and skin structure infections or 
bacteremia. Antimicrob Agents Chemother 2009;53:4422-8. 
22. Belley A, Francis FA, Sarmiento I, Hong D, Warren R, Greg M, et al. 
Pharmacodynamics of a simulated single 1,200-milligram dose of 
oritavancin in an in vitro pharmacokinetic/pharmacodynamic 
model of methicillin-resistant Staphylococcus aureusinfection. J 
Antimicrob Chemother 2013;57:205–11. 
23. Seltzer E. Once-weekly dalbavancin versus standard-of-care 
antimicrobial regimens for treatment of skin and soft-tissue 
infections. Clin Infect Dis 2003;37:1298–303. 
24. Jauregui LE, Simon B, Elyse S, Lisa G, Dainis K, Mark F, et al. 
Randomized, double-blind comparison of once-weekly 
dalbavancin versus twice-daily linezolid therapy for the 
treatment of complicated skin and skin structure infections. 
Clin Infect Dis 2005;41:1407–15. 
25. Dorr MB, Daniela J, Marco C, James D, Giorgio M, Adriano M, et 
al. Human pharmacokinetics and rationale for once-weekly 
dosing of dalbavancin, a semi-synthetic glycopeptide. J 
Antimicrob Chemother 2005;55:25–30. 
26. Helen WB, Mark W, George HT, Sailaja P, Anita FD, Michael W, et al. 
Once-weekly dalbavancin versus daily conventionaltherapy for 
skin infection. N Engl J Med 2014;370:2169–79. 
27. FDA. FDA approves new antibacterial drug Zerbaxa; 2014. 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnounce
ments/ucm427534.htm. [Last accessed on 08 Jul 2017] 
28. Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of 
acidic pH on the extracellular and intracellular activities of the 
anti-gram-positive fluoroquinolonesmoxifloxacin and 
delafloxacin against Staphylococcus aureus. Antimicrob Agents 
Chemother 2011;55:649–58. 
29. Siala W, Marie P, Francoise V, Paul MT, Marie H, Oliver D, et al. 
Antibiotic activity against biofilms from Staphylococcus aureus 
clinical isolates: factors determining the activity of the 
investigational fluoroquinolone delafloxacin in comparison 
with daptomycin and vancomycin. Antimicrob Agents 
Chemother 2014;58:6385–97. 
30. Citeline. “Pharmaprojects; 2012. Available from: http://www. 
citeline.com/products/pharmaprojecs. [Last accessed on 08 Jul 
2017]. 
31. Helen WB, George HT, Daniel KB, John B, Robert JG, et al. “10 x ’20 
progress—development of new drugs active against gram-
negative bacilli: an update from the infectious diseases society 
of America. Clin Infect Dis 2013;56:1685–94. 
 
